ICBI UPDATE ON THE ROAD TO THE CURE

UPDATE ON PARKINSON’S “ROAD TO THE CURE” PROJECT Justifying funding the ICBI Parkinson’s drug for clinical trials according to Ram Bhatt, PhD, “ICBI continues to make progress in bringing its Parkinson’s drug nearer and nearer to closing the gap between today and delivering it to the people…” Big Pharmaceutical Company Monitoring ICBI … [Read more...]

ICBI UPDATE ON THE ROAD TO THE CURE

By:Ram S. Bhatt, PhD, CEO & CSO PROS AND CONS OF STEM CELL THERAPY PROS AND CONS OF STEM CELL THERAPY Back in 2007 (10 years ago) Jim Fossett, of AMBI/Rockefeller Institute, Federalism and Bioethics Initiative, compiled data on the amount of money being spent on Stem Cell research: Allocations, via NIH, have been roughly flat at $640 … [Read more...]

UPDATE ON PARKINSON’S “ROAD TO THE CURE” PROJECT

UPDATE ON PARKINSON’S “ROAD TO THE CURE” PROJECT Ram S. Bhatt, CSO, CEO “...the biologics (drugs) capable of modifying and/or halting the brain diseases are prevented from entering the brain... ICBII’s SMART Molecules … making it the first company in the world to detect… and stop its expression…” This is an exciting time in the scientific … [Read more...]

DECEMBER UPDATE ON PARKINSON’S “ROAD TO A CURE” PROJECT

Ram S. Bhatt, CSO, CEO “Our plans are to take our drug to the patients… before starting clinical…” ICBI-Pharma Collaboration   We have a Material Transfer Agreement (MTA) with a large pharmaceutical company to affirm our efforts and findings in their laboratory. This process was agreed upon prior to their making a possible offer to ICBI. … [Read more...]

NOVEMBER UPDATE ON ROAD TO THE CURE

THE ROAD TO THE CURE DRUG DEVELOPMENT AND THE ROAD TO THE US FDA By Ram Bhatt, CSO ICBI, Inc. ICBI SMART Molecules (SMs) technology is poised to translate our most promising scientific breakthroughs into meaningful disease altering treatments capable of tackling the most complex and vexing medical challenges related to the diseases of the … [Read more...]